NEW YORK STOCK EXCHANGE, INC. · ANVS
+1.34% · +$0.0250 · Vol 1.0M
Live · updated 15:20:21 ET
Annovis Bio Inc

Annovis Bio Inc

Biotechnology
$1.90
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
ANVS
Annovis Bio Inc
Tue Aug 4 · last completed session · daily score · 21h old
SELL BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

31/ 100
Veridion Score
SELL BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Tue Aug 4 · last completed session · daily score · 21h old
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ANVS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ANVS catalysts
About Annovis Bio Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
7
Country
US

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.90
Day high
$1.98
Day low
$1.89
Previous close
$1.87
52W high
$5.10
-62.84% from high
52W low
$1.59
9% of range
Market cap
$79.6M
EPS
$-1.6400
Beta
1.70
Shares out
42.5M
Volume
1M
1.25× rel vol
Avg volume
807.1K
VWAP
$1.93
Price history computed in-house
1W
+11.47%
1M
-3.81%
3M
-16.15%
1Y
-30.33%
YTD
-45.23%
SMA 50 $1.82 · above
SMA 200 $2.50 · below
52W position 9%

ANVS overview

Veridion Score
31
5 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ANVS.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ANVS Form 4 filings
Public disclosures

Congress activity in ANVS

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ANVS in the cached public ledger.

Federal contracts

ANVS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ANVS in this window.
Lobbying spend

ANVS lobbying filings, year to date.

Registered lobbying filings matched to Annovis Bio Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ANVS in this window.
Loading news for ANVS
Analyst ratings
Sovereign unlock shows live analyst consensus for ANVS.
Options
Sovereign unlock shows live options positioning for ANVS.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.